Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 8—August 2004
Research

Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000

Dominique L. Monnet*, Fiona M. MacKenzie†Comments to Author , José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Aberdeen Royal Infirmary, Aberdeen, Scotland; ‡Hospital Vega Baja, Orihuela (Alicante), Spain; §University of Murcia, Murcia, Spain

Main Article

Table 3

Summary of transfer function models explaining the monthly %MRSA by use of each antimicrobial drug classa

Antimicrobial classb Average delay (months) Direction of effectc p value R2d
Combinations of penicillins with β-lactamase inhibitors
2
4
Positive
Positive
0.04
0.01
0.92
β-lactamase-resistant penicillins
0
6
Negative
Positive
0.02
0.002
0.90
Macrolides
1
Positive
0.0001
0.93
Penicillins with extended spectrum
1
Positive
0.03
0.91
Third-generation cephalosporins
1
Positive
0.04
0.90
β−lactamase sensitive penicillins
6
Positive
0.04
0.89
Combinations of sulfonamides and trimethoprim, including derivatives
4
Positive
0.02
0.90
Fluoroquinolones
4
Positive
0.0004
0.92
Second-generation cephalosporins
No relationship
Other antibacterialsd
0
Positive
0.002
0.91
Tetracyclines
4
7
Positive
Negative
0.03
0.0007
0.91
Aminoglycosides
No relationship
Lincosamides
7
Positive
0.02
0.89
First-generation cephalosporins
No relationship
Carbapenems 3 Positive 0.03 0.90

aMRSA, methicillin-resistant Staphylococcus aureus.
bGlycopeptide use is not presented in this table because it showed an inverse relationship with %MRSA. In other words, %MRSA explained the monthly variations of glycopeptide use and not the reverse (Discussion).
cPositive direction of effect: increase in antimicrobial use results in increase in %MRSA and inversely. Negative direction of effect: increase in antimicrobial use results in decrease in %MRSA and inversely.
dAll models include the variable %MRSA with a 1-month delay with a p value < 0.0001.
dAmphenicols, monobactams, other quinolones, imidazoles, fusidic acid, and nitrofurantoin derivatives.

Main Article

Page created: March 01, 2011
Page updated: March 01, 2011
Page reviewed: March 01, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external